In-stent restenosis corresponds to the diameter reduction of coronary vessels following percutaneous coronary intervention (PCI), an invasive procedure in which a stent is deployed into the coronary arteries, producing profuse neointimal hyperplasia. The reasons for this process to occur still lack a clear answer, which is partly why it remains as a clinically significant problem. As a consequence, there is a vigorous need to identify useful non-invasive biomarkers to differentiate and follow-up subjects at risk of developing restenosis, and due to their extraordinary stability in several bodily fluids, microRNA research has received extensive attention to accomplish this task. This review depicts the current understanding, diagnostic potential and clinical challenges of microRNA molecules as possible blood-based restenosis biomarkers.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6967329 | PMC |
| http://dx.doi.org/10.3389/fgene.2019.01247 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inflammatory-Related Biomarkers in Patients Undergoing Percutaneous Transluminal Angioplasty for Femoropopliteal Artery Lesions.
Acta Cardiol Sin
January 2025
Department of Cardiology, Gebze State Hospital, Gebze.
Article Synopsis
- The study investigated the role of inflammation-related biomarkers (SII, SIRI, NLR, PLR) in predicting mid-term mortality and restenosis in patients with peripheral artery disease (PAD).
- During an average follow-up of about 21 months, researchers found that higher levels of these biomarkers correlated with increased mortality rates, particularly highlighting NLR as a significant independent risk factor.
- However, no significant links were established between these biomarkers and the occurrence of restenosis in the study participants.
Correlation Between Lipoprotein(a) and Prognosis for Coronary Artery Disease in Patients Undergoing Percutaneous Coronary Intervention.
Tex Heart Inst J
December 2024
Department of Cardiology, Daping Hospital, The Third Military Medical University (Army Medical University), Chongqing, People's Republic of China.
Background: Elevated lipoprotein(a) (Lp[a]) is a risk factor for first atherosclerotic thrombosis events, but the role of elevated Lp(a) in secondary prevention is controversial. This study aimed to retrospectively investigate the influence of elevated Lp(a) levels on the prognosis of patients with coronary artery disease.
Methods: The team collected and compared clinical information of patients hospitalized during percutaneous coronary intervention (PCI).
Advancements in Mesenchymal Stem Cell-Based Therapy for Enhancing Arteriovenous Fistula Patency.
Int J Mol Sci
November 2024
Vascular and Interventional Radiology Translational Laboratory, Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
Chronic kidney disease (CKD) affects more than 10% of the world's population. Hemodialysis, along with peritoneal dialysis and renal transplant, is one of the renal replacement therapies offered to patients with CKD/end-stage renal disease (ESRD). To proceed with hemodialysis, vascular access is required.
View Article and Find Full Text PDFMonocyte to high-density lipoprotein cholesterol ratio predicts restenosis of drug-eluting stents in patients with unstable angina pectoris.
Sci Rep
December 2024
Department of Cardiology, Tianjin Chest Hospital, No.261 of Taierzhuangnan Road, Jinnan District, Tianjin, 300222, People's Republic of China.
Article Synopsis
- - Several studies have hinted that the ratio of monocyte count to high-density lipoprotein cholesterol (MHR) can help predict in-stent restenosis (ISR) in patients with bare-metal stents; however, its effectiveness for drug-eluting stents (DES) is less clear.
- - This study focused on 474 patients with unstable angina who received DES between 2014 and 2022, dividing them into ISR and non-ISR groups to assess the predictive value of MHR, which was found to be significantly higher in the ISR group.
- - The results indicated that MHR could independently predict ISR with good sensitivity and specificity, and including MHR in predictive models improved their accuracy, suggesting it could be a
International Consensus Statement on Platelet Function and Genetic Testing in Percutaneous Coronary Intervention: 2024 Update.
JACC Cardiovasc Interv
November 2024
Medizinische Klinik und Poliklinik I, University Hospital Munich, Ludwig-Maximilians University, Munich, Germany; Privatklinik Lauterbacher Mühle am Ostsee, Seeshaupt, Germany.
Current evidence indicates that dual antiplatelet therapy with aspirin plus a P2Y inhibitor is essential for the prevention of thrombotic events after percutaneous coronary interventions. However, dual antiplatelet therapy is associated with increased bleeding which may outweigh the benefits. This has set the foundations for customizing antiplatelet treatments to the individual patient.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!